Study says DPP-IV benefits may go beyond diabetes

Share this article:

DPP-IV diabetes medications may have benefits beyond insulin control. PharmaTimes reports that a Brigham and Women's Hospital study shows the medications may be associated with a reduced risk of autoimmune diseases among type-2 diabetics. PT says researcher Seoyoung Kim told reporters at the American College of Rheumatology conference that diabetics taking DPP-IV combination therapy were 34% less likely to develop RA and reduced their risk of other autoimmune diseases by 27%.

PT notes that the study is not definitive, but further evidence would benefit Merck's Januvia (which has seen sales slide) and the Boehringer Ingelheim/Eli Lilly drug Tradjenta. The DPP-IV class also includes the Bristol-Myers Squibb/AstraZeneca drug Onglyza.

The diabetes category as a whole is getting tighter. Merck noted in its conference call, for example, that "the DPP-IV market and branded worldwide diabetic market isn't growing." Additional pressures, such as being squeezed out of PBM formulary offerings have added to category pressures.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.